PPD, Inc. announced it has entered into an exclusive alliance with DiabetesAmerica, a provider of comprehensive diabetes care services based in Houston, Texas. Under the agreement, PPD will provide clinical research training and support to more than 20 clinical trial investigators who will conduct Type 1 and Type 2 diabetes clinical trials from DiabetesAmerica's 17 centers across Texas and Arizona.
In return, DiabetesAmerica will work exclusively with PPD to provide clinical research services for endocrine and metabolic disease development programs over a minimum of three years. The agreement expands PPD's ability to recruit for diabetes-related clinical trials through the use of DiabetesAmerica's 16,000-plus patient database.
"Diabetes is a disease with serious complications that affects more than 23 million Americans," said Mike Wilkinson, executive vice president of clinical development at PPD. "We are pleased to assist these physicians in bringing cutting-edge diabetes treatments to their patients through training and support. In addition, DiabetesAmerica's patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease."
"DiabetesAmerica is committed to delivering the latest treatments in diabetes care to our patients," said Rosemary Mazanet, MD, PhD, and CEO of DiabetesAmerica. "Our alliance with PPD will help ensure our physicians are fully trained on managing drug development programs so we can continue to bring complete diabetes care to our patients."
See a free diabetes and obesity podcast series to learn more about clinical trials in these therapeutic areas.